Malaria - From the heart of Europe to the Tropics (2010)
Malaria is considered to be a tropical disease today. In earlier days, however, it also caused much suffering in Europe. The marshes and moors of Northern Germany were dreaded malaria-infested regions up to the 19th century. Every second child in East Frisia is suspected to have been infected with the marsh fever during the epidemic in 1826. Similarly, outbreaks of malaria were quite frequent at the Upper Rhine. Fortunately, this is a thing of the past. On the southern hemisphere though, malaria is still harsh reality even today. Almost one million people die of a fatal mosquito bite each year, every 30 seconds a child dies. That is reason enough to take a look at the disease.
This Pharma-Brief Special gives information on prevention, therapy and supply problems, provides the background on current research projects and describes the history of malaria between colonial politics and military interests.
Download Brochure [PDF/ 1,1MB]
At any price? - Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in India (2011)
BUKO Pharma-Kampagne and the Institute of Public Health Bangalore/ India have made a survey of the business behavior of Bayer Health Care, Boehringer Ingelheim and Baxter in India. The results: these companies sell many irrational preparations and offer only few essential innovations. Bayer and Boehringer Ingelheim conduct numerous clinical trials in India, but they prefer to search for new applications of their blockbusters instead of doing research in the field of neglected diseases. Boehringer Ingelheim has a particularly poor pharmaceutical portfolio with 70% of irrational drugs and no essential preparation. Other topics of the survey focus on patent policies and marketing practices.
Download Brochure [PDF/ 1,5MB]
Update 26.9.2012: Boehringer reacts
Poor and forgotten - Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda (2014)
BUKO Pharma-Kampagne and HEPS Uganda have scrutinised the business behaviour of the pharma companies Bayer, Boehringer Ingelheim and Baxter in Uganda. The conclusion: The brand manufacturers have no or only little interest in supplying a country without solvent patients with drugs or in getting involved in research there. While Baxter has already given up on the Ugandan market, Boehringer Ingelheim is planning to retreat. Only Bayer carries on selling drugs in Uganda – among them several hormone preparations and contraceptives, some of them of rather dubious benefit. This study presents valid facts and analyses concerning Uganda and raises important questions actors and deciders in development and health policy have to face: For instance, how can you fill gaps in supply while the free market fails? How can you consolidate local production?
Download: Brochure [PDF/2,1 mB]
Antibiotic resistance: a global challenge (2015)
Antibiotics have been a blessing for medicine. Their discovery meant that infections which had previously caused great suffering and many deaths could now be treated. But the situation is changing dramatically, with more and more bacteria becoming resistant to an increasing number of active agents used in antibiotics. Every year tens of thousands of people die worldwide as a result of multiresistant microbes. And resistance does not stop at national borders: it develops anywhere and can spread anywhere.
This is why any attempts to resolve the problem of resistance must be as global as its causes. The slogan 'One Health' must be understood in the broadest terms: the Global North and Global South, human and veterinary medicine, social components and technical solutions must be considered.
Download Brochure [PDF/2,8mB]
Spezial 2/2017: Weniger Medikamente - bessere Behandlung
(22.11.2017) Vor 40 Jahren veröffentlichte die Weltgesundheitsorganisation (WHO) die erste Modellliste unentbehrlicher Arzneimittel. Ärmere Länder hatten die Unterstützung der WHO bei der Auswahl sinnvoller Präparate schon länger gefordert und teils schon selbst nationale Listen eingeführt. Die WHO-Liste löste bei Big Pharma einen Sturm der Empörung aus, seien doch alle Medikamente gleichermaßen für die Behandlung geeignet.
Download: Pharma-Brief Spezial 2/2017 Weniger Medikamente - bessere Behandlung [PDF]
Pharma-Brief Spezial
Hier finden Sie eine separate Auflistung des Pharma-Brief Spezial. Dies sind Sonderausgaben, die sich auf unterschiedliche Themenschwerpunkte konzentrieren.
Pharma-Brief Archiv
Pharma-Brief Archiv
Unsere Fachzeitschrift Pharma-Brief erscheint acht Mal pro Jahr und bietet gut recherchierte Beiträge rund um das Thema globale Gesundheit. Sie informiert über Zugangsprobleme bei Medikamenten, Arzneimittelrisiken und Nutzenbewertung, mangelnde Transparenz des Arzneimittelmarktes, vernachlässigte Krankheiten, illegale Pharmageschäfte, internationale Gesundheitspolitik und auch über Projekte der BUKO Pharma-Kampagne. Zweimal jährlich erscheint außerdem eine Doppelausgabe mit dem Pharma-Brief Spezial als Beilage. Die Broschüren beleuchten jeweils ein Schwerpunktthema.
Abonnieren Sie den Pharma-Brief und bleiben Sie auf dem Laufenden!
Sie können hier alle Jahrgänge des Pharma-Briefes ab 1981 online lesen.